Analysts expect that Horizon Pharma PLC (NASDAQ:HZNP) will announce $0.22 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Horizon Pharma’s earnings. The lowest EPS estimate is $0.19 and the highest is $0.24. Horizon Pharma posted earnings per share of $0.66 in the same quarter last year, which indicates a negative year-over-year growth rate of 66.7%. The company is scheduled to announce its next quarterly earnings report before the market opens on Wednesday, February 28th.
According to Zacks, analysts expect that Horizon Pharma will report full-year earnings of $1.09 per share for the current financial year, with EPS estimates ranging from $1.04 to $1.13. For the next financial year, analysts expect that the firm will report earnings of $1.30 per share, with EPS estimates ranging from $1.04 to $1.42. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Horizon Pharma.
Several analysts recently issued reports on the stock. Cantor Fitzgerald set a $17.00 price objective on shares of Horizon Pharma and gave the company a “buy” rating in a report on Monday, January 8th. Mizuho upgraded shares of Horizon Pharma from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $12.00 to $18.00 in a report on Friday, January 12th. BidaskClub upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. ValuEngine lowered shares of Horizon Pharma from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Jefferies Group boosted their price objective on shares of Horizon Pharma from $16.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $19.25.
Shares of Horizon Pharma (NASDAQ HZNP) traded up $0.14 on Friday, reaching $14.10. 1,036,471 shares of the company traded hands, compared to its average volume of 1,558,121. The stock has a market cap of $2,287.85, a price-to-earnings ratio of -4.62, a P/E/G ratio of 0.65 and a beta of 1.35. Horizon Pharma has a 12-month low of $9.45 and a 12-month high of $17.69. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64.
Large investors have recently modified their holdings of the business. Sei Investments Co. increased its stake in Horizon Pharma by 68.5% during the third quarter. Sei Investments Co. now owns 391,170 shares of the biopharmaceutical company’s stock worth $4,961,000 after purchasing an additional 159,002 shares during the period. Canada Pension Plan Investment Board increased its stake in Horizon Pharma by 348.9% during the third quarter. Canada Pension Plan Investment Board now owns 101,900 shares of the biopharmaceutical company’s stock worth $1,292,000 after purchasing an additional 79,200 shares during the period. American International Group Inc. increased its stake in Horizon Pharma by 8.1% during the third quarter. American International Group Inc. now owns 109,477 shares of the biopharmaceutical company’s stock worth $1,388,000 after purchasing an additional 8,185 shares during the period. Wells Fargo & Company MN increased its stake in Horizon Pharma by 24.8% during the third quarter. Wells Fargo & Company MN now owns 456,169 shares of the biopharmaceutical company’s stock worth $5,784,000 after purchasing an additional 90,692 shares during the period. Finally, Chicago Equity Partners LLC purchased a new stake in Horizon Pharma during the third quarter worth about $1,726,000. Institutional investors own 84.39% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Horizon Pharma PLC (HZNP) Will Post Earnings of $0.22 Per Share” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/24/analysts-anticipate-horizon-pharma-plc-hznp-will-post-earnings-of-0-22-per-share.html.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Get a free copy of the Zacks research report on Horizon Pharma (HZNP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.